- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor Which conditions qualify? The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
- News News
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Reports 2020 State of the States Medical Cannabis Access for Pain Treatment Medical Cannabis in America Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit
- Join Join
OAKLAND – Today’s issue of Time magazine reports that new research on the medical use of marijuana is one of the most significant medical developments of 2005. This article comes just one week after the final deadline for response to a legal challenge brought by a medical marijuana advocacy group that asks the federal Department of Health and Human Services (HHS) to stop claiming there is no medical use for marijuana.
According to Time, “Research into the analgesic and anti-inflammatory effects of cannabis continued to bolster the case for the medicinal use of marijuana, making the ‘patient pot laws’ that have passed in 11 states seem less like a social movement than a legitimate medical trend. One trial--the first controlled study of its kind--showed that a medicine containing cannabis extracts called Sativex not only lessened the pain of rheumatoid arthritis but actually suppressed the disease. An earlier study published in the Journal of Neuroscience showed that synthetic cannabinoids, the chemicals in marijuana, can reduce inflammation in the brain and may protect it from the cognitive decline associated with Alzheimer's disease.”
Despite the widespread acceptance of scientific research like this, the federal government continues to claim that there is no medical use for marijuana. That claim is being challenged by Americans for Safe Access, an Oakland-based medical marijuana advocacy group. HHS has yet to respond to the medical marijuana group’s administrative appeal of HHS’s earlier denial of its petition under the Data Quality Act, requesting the department correct its statements that marijuana is not considered to have medical value. As a result, Americans for Safe Access is preparing to sue HHS for its failure to respond. The appeal has been pending since last May, even though the department’s guidelines specify that it will respond to such requests within 60 calendar days.
“The government’s failure to meet its obligations under the DQA is a violation of its own procedures,” said Steph Sherer, ASA’s executive director. “HHS should not be standing in the way of medical advances.”
The Administrative Procedure Act allows judicial review to compel agency action when such action is “unreasonably” delayed. If Americans for Safe Access prevails in its petition, the Department of Health and Human Services will have to change its published information on medical marijuana and publicly admit that marijuana is now effectively used for medical treatment, clearing the way for medical reclassification that would allow doctors to prescribe it to their patients nationwide.
The United Kingdom reclassified marijuana from class B to class C in 2004, meaning they have determined marijuana has a low risk of addiction and few long-term health hazards. After one year, the government's Advisory Council on the Misuse of Drugs affirmed the reclassification. Despite concerns that reducing criminal penalties would increase use, the number of people using cannabis has fallen by more than 1% in the first full year after possession of the drug was made a less serious offense, and the UK has reportedly freed-up police resources to fight hard drugs such as heroin and cocaine.
# # # #